Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 5Myeloid 3Classical hematology 2

Conditions

Anemia, Refractory, with Excess of Blasts 14Myelodysplastic Syndromes 10Leukemia, Myeloid, Acute 10Leukemia, Myelomonocytic, Chronic 8Leukemia 6Anemia, Refractory 4Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2GATA2 Deficiency 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Hematologic Diseases 1Congenital Abnormalities 1

Interventions

Azacitidine 2venetoclax 1Vorinostat 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
GATA2 Deficiency × Azacitidine × Classical hematology × Clear all
NCT01522976 2026-04-30

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT06372717 2026-02-04

A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

Apollo Therapeutics Ltd

Phase 1 Recruiting
100 enrolled
Classical hematologyOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡